Immunogenicity Studies for Biotherapeutics
title
Agenda Day Two
For complete information, including full descriptions of the following sessions, please download the conference brochure.
|
Technology |
|
| 8:00 | Morning Coffee |
| 8:15 | Chairpersons' Recap of Day One |
| 8:30 |
Immunogenicity of Protein Therapeutics in a Global Context Philippe Stas, PhD, Chief Operating Officer, ALGONOMICS |
| 9:00 |
Bridge or Not Bridge: Lessons Learned From Selection of ELISA Formats For Measuring Immunogenicity of a Therapeutic Protein in Preclinical And Clinical Trials Xing Li, PhD, Senior Scientist, VIRON THERAPEUTICS |
| 9:30 |
Immunogenicity Validation for a Protein Therapeutic, Case Study of Sandwich ELISA and Sample Analysis: Lessons Learned Lynne LeSauteur, PhD, Scientific Director, Immunology, Laboratory Sciences, CHARLES RIVER LABORATORIES PRECLINICAL SERVICES |
| 10:00 |
30-Minute Morning Break |
| 10:30 |
Comparison of Enzyme-linked and Electrochemiluminescent Immunoassays Deborah Finco-Kent, Immunoassay Coordinator, Immunotoxicology Lab, Safety Sciences, PFIZER |
| 11:00 |
Novel Approaches to Overcoming Immunogenicity Challenges Pankaj Oberoi, PhD, Director, Scientific Service, MESOSCALE DISCOVERY |
| 11:30 |
Assay Comparison Panel Discussion
Panelists:
An Song, PhD, Scientist, GENENTECH Michael Moxness, PhD, DABCC, Principal Scientist, AMGEN Pankaj Oberoi, PhD, Director, Scientific Services, MESOSCALE DISCOVERY |
| 12:15 | Networking Luncheon |
| 1:15 |
Panel Discussion Panelists represent:
CHARLES RIVER LABORATORIES |
|
1:45
2:15
|
Strategies for the Rational Development of a Pre-Clinical Immunogenicity-Testing Platform Maria Barbosa, Ph.D. President and CEO. CA CONSULTANTS Pre-Clinical Assessment and "De-Risking" of Immunogenicity Harald Kropshofer, PhD, Global Coordinator Immunosafety, F. HOFFMANN LA ROCHE |
| 3:00 |
Conference Concludes |
Bottom menu
Copyright 2003-2006 IIR Holdings, Ltd. All rights Reserved